Literature DB >> 12662016

Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer.

E Radzikowska1, E Szczepulska, M Chabowski, I Bestry.   

Abstract

The case of a 49-yr-old female, who developed fever, effort dyspnoea and cough, with patchy migratory bilateral pulmonary infiltrates 6 weeks after starting transtuzumab therapy, following breast-conserving surgery with adjuvant chemoradiotherapy and hormone therapy for breast carcinoma, is reported here. Chest radiograph and thin section computed tomography demonstrated alveolar opacities with air bronchogram in both lungs. A lung biopsy was performed in a nonirradiated area of the contralateral lung and revealed a typical histological pattern of organising pneumonia (previously known as bronchiolitis obliterans organising pneumonia). Transtuzumab therapy was discontinued and subsequent gradual clinical and radiological improvement was observed. After 3 months, complete resolution of symptoms and radiographical abnormalities were noted. This is the first case report that suggests that transtuzumab therapy might induce the development of lung infiltrates with the histological appearance of organising pneumonia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12662016     DOI: 10.1183/09031936.03.00035502

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  18 in total

Review 1.  Systematic review of postradiotherapy bronchiolitis obliterans organizing pneumonia in women with breast cancer.

Authors:  Gary R Epler; Eileen M Kelly
Journal:  Oncologist       Date:  2014-10-31

2.  Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer.

Authors:  Xavier Hernández Yagüe; Ester Soy; Bernardo Queralt Merino; Josep Puig; Miguel Beltrán Fabregat; Ramón Colomer
Journal:  Clin Transl Oncol       Date:  2005-12       Impact factor: 3.405

3.  Interstitial lung disease associated with trastuzumab monotherapy: A report of 3 cases.

Authors:  Akinori Sugaya; Shingo Ishiguro; Shoichi Mitsuhashi; Masahiro Abe; Ikuta Hashimoto; Takayuki Kaburagi; Hiroshi Kojima
Journal:  Mol Clin Oncol       Date:  2016-12-19

Review 4.  Interstitial lung disease in lung cancer: separating disease progression from treatment effects.

Authors:  Sarah Danson; Fiona Blackhall; Paul Hulse; Malcolm Ranson
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  Analysis of kinase gene expression patterns across 5681 human tissue samples reveals functional genomic taxonomy of the kinome.

Authors:  Sami Kilpinen; Kalle Ojala; Olli Kallioniemi
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

6.  Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.

Authors:  Michele Y Halyard; Thomas M Pisansky; Amylou C Dueck; Vera Suman; Lori Pierce; Larry Solin; Larry Marks; Nancy Davidson; Silvana Martino; Peter Kaufman; Leila Kutteh; Shaker R Dakhil; Edith A Perez
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

Review 7.  Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.

Authors:  Mizuki Nishino; Hiroto Hatabu; Lynette M Sholl; Nikhil H Ramaiya
Journal:  Radiographics       Date:  2017 Sep-Oct       Impact factor: 5.333

Review 8.  Anticancer therapy and lung injury: molecular mechanisms.

Authors:  Li Li; Henry Mok; Pavan Jhaveri; Mark D Bonnen; Andrew G Sikora; N Tony Eissa; Ritsuko U Komaki; Yohannes T Ghebre
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-23       Impact factor: 4.512

9.  Delayed Paclitaxel-trastuzumab-induced interstitial pneumonitis in breast cancer.

Authors:  Omalkhair Abulkhair; Wael El Melouk
Journal:  Case Rep Oncol       Date:  2011-04-02

10.  Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu.

Authors:  Joan Tymon-Rosario; Eric R Siegel; Stefania Bellone; Justin Harold; Naomi Adjei; Burak Zeybek; Dennis Mauricio; Gary Altwerger; Gulden Menderes; Elena Ratner; Mitchell Clark; Vaagn Andikyan; Gloria S Huang; Masoud Azodi; Peter E Schwartz; Amanda N Fader; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2021-08-06       Impact factor: 5.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.